
Summary
Abnormal AI has 2 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is FedRAMP: FedRAMP Authorized. This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.
Reviewer brief
As of 17 Sep 2026, Abnormal AI (abnormal.ai) is listed in the FedRAMP registry as FedRAMP Authorized, with the authorization issued 11 Apr 2025 and audited by Schellman Compliance, LLC. As of 17 Sep 2026, Abnormal AI is also listed in the CSA STAR registry with a STAR Level 1 self-assessment (CAIQ) and Trusted Cloud Provider designation, issued 25 Jan 2023. As of 17 Sep 2026, no expiration date is provided for either the FedRAMP or CSA STAR entries. As of 17 Sep 2026, no public evidence found for SOC 2 status for Abnormal AI. As of 17 Sep 2026, no public evidence found for HIPAA status for Abnormal AI.
- FedRAMP: listed in FedRAMP registry as FedRAMP Authorized, issued 11 Apr 2025, audited by Schellman Compliance, LLC (as of 17 Sep 2026).
- CSA STAR: listed in CSA STAR registry with STAR Level 1 self-assessment (CAIQ), Trusted Cloud Provider status, issued 25 Jan 2023 (as of 17 Sep 2026).
- SOC 2 and HIPAA: no public evidence found for either framework (as of 17 Sep 2026).
Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.
Among security vendors
2verified rows
Category median 1, across 174 indexed security vendors. Abnormal AI has more verified rows than 91 percent of them.
ai-poweredattack preventionemail securitythreat detection
Compare with similar vendors
Pick your own comparisonCompliance grid
Legal artefacts
No DPA, BAA or subprocessor list has been captured from a public page yet. Registry rows above do not depend on this. Check the vendor trust centre.
Subprocessors
No subprocessor list captured yet.
Similar vendors with evidence
Related by product tags and the Security category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.